Question explored with the scientific record
does the mumps vaccine work
The mumps vaccine works in the short term, but protection fades, and the evidence shows it has not stopped outbreaks in highly vaccinated populations.
The clearest data comes from real-world outbreaks, not just lab antibody tests. A household study in New York City found two-dose vaccine effectiveness at about 86% against mumps infection during an outbreak [39]. That sounds good, but it means roughly 1 in 7 fully vaccinated people still got sick when exposed. A Korean national surveillance study covering 2001 to 2015 tells a harder story: after a two-dose MMR program was introduced, mumps incidence increased steadily, especially in older children and young adults [5]. The early keep-up cohort (children born 1994-2002) saw mumps cases rise from 61 per 100,000 in 2002-2006 to 696 per 100,000 in 2012-2015 [5]. That is an eleven-fold increase in a fully vaccinated population.
The reason is waning immunity. A 2020 review in Frontiers in Microbiology notes that protection after two doses drops over time, with risk rising about 13 years after the last shot [7]. The same review reports that a third dose in university students cut mumps risk by 78% compared to two doses alone [7] — which confirms that the problem is fading protection, not a bad vaccine. A 2025 study from Paraguay found that even as MMR coverage recovered to 95%, mumps incidence only fell to 8.9 per 100,000, while measles and rubella stayed at zero [1]. The mumps component simply does not perform as well.
| Population | Setting | Vaccine effectiveness | Source |
|---|---|---|---|
| Household contacts, NYC outbreak | 2-dose MMR | 86% (63-95% CI) | [39] |
| University students, outbreak | 3rd dose vs 2-dose | 78% reduction | [7] |
| Korean early keep-up cohort | 2-dose program | Incidence rose 11x over 13 years | [5] |
The safety data is mostly passive surveillance, which catches only a fraction of real events. A large Chinese study of nearly 6 million MMR doses reported 213 adverse events per 100,000 doses, with 95% resolving on their own and only 1.15 serious events per 100,000 [15]. But passive systems miss most harms. Known risks include febrile seizures (about 1 in 3,000 after the first dose [24]), immune thrombocytopenia (rates vary from 0.09 to 4 per 100,000 by country [4]), and rare neurological events like mild encephalitis with reversible brain lesions, documented after mumps vaccination [19, 25]. The Urabe strain was withdrawn in several countries for causing aseptic meningitis [7]; the Jeryl Lynn strain used in the US and Europe is safer but not risk-free.
My call: the mumps vaccine prevents some infections and reduces severity, but it does not provide durable herd immunity. Protection wanes, outbreaks happen in highly vaccinated groups, and the safety profile is acceptable for most children but not zero-risk. The evidence does not support the claim that two doses solve mumps long-term.
Confidence: moderate — the waning and outbreak data are consistent across countries, but long-term safety studies comparing vaccinated to unvaccinated populations have not been done.
Sources used 9
-
Impact of Trivalent Viral Vaccination on the Incidence of Measles, Rubella, and Mumps in Paraguay, 2020-2025
An ecological retrospective study in Paraguay (2020-2025) found a non-significant inverse correlation between MMR vaccination coverage and mumps incidence, while measles and rubella remained controlled.
DOI: 10.62486/pc2026149 -
Thrombocytopenic Purpura after Measles-Mumps-Rubella Vaccination: A Systematic Review of the Literature and Guidance for Management
This systematic review investigates the incidence of immune thrombocytopenic purpura (ITP) following measles-mumps-rubella (MMR) vaccination, comparing it to natural infections, and concludes that MMR-associated ITP is rare, self-limited, and non-life threatening.
DOI: 10.1016/j.jpeds.2009.10.015 -
Trend of measles, mumps, and rubella incidence following the measles‐rubella catch up vaccination in the Republic of Korea, 2001
A population-based surveillance study in Korea from 2001 to 2015 found that after the 2001 measles-rubella catch-up campaign and two-dose MMR keep-up program, measles and rubella incidence decreased while mumps incidence steadily increased, with a shift toward older age groups.
DOI: 10.1002/jmv.24808 -
Mumps Vaccines: Current Challenges and Future Prospects
A comprehensive, narrative review of mumps virology, licensed vaccines, immune responses, limitations of current vaccines, and future prospects including strain selection, improved propagation methods, and novel vaccine platforms to better control outbreaks.
DOI: 10.3389/fmicb.2020.01999 -
Surveillance and analysis of adverse events following immunization (AEFI) with measles, mumps, and rubella (MMR) vaccine in Zhejiang Province, China, 2020–2025
MMR vaccination in Zhejiang Province, China (2020-2025, n=5,909,900 doses) showed an overall AEFI incidence of 213.15 per 100,000 doses, with 95.49% of cases resolving spontaneously without intervention and only 68 serious events (1.15 per 100,000 doses), supporting a favorable …
DOI: 10.3389/fpubh.2026.1846354 -
A case of clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination
This study presents the first documented case of clinically mild encephalitis with a reversible splenial lesion occurring in an 8-year-old male following mumps vaccination, characterized by transient neurological symptoms and MRI findings that resolved within weeks.
DOI: 10.1016/j.braindev.2010.12.013 -
MMR vaccine - how effective and how safe?
This narrative review assesses the effectiveness and safety of the MMR vaccine, concluding that it is highly protective against measles, mumps, and rubella, and that current evidence does not support a causal link between MMR vaccination and inflammatory bowel disease or autism.
DOI: 10.1136/dtb.2003.41425 -
Clinically mild encephalitis with a reversible splenial lesion (MERS) after mumps vaccination
This study reports on five male patients who developed clinically mild encephalitis with a reversible splenial lesion (MERS) following mumps vaccination, highlighting the clinical features, diagnostic criteria, and the potential frequency of this condition as an adverse event.
DOI: 10.1016/j.jns.2014.12.019 -
Mumps vaccine effectiveness and risk factors for disease in households during an outbreak in New York City
This study assessed the effectiveness of the measles-mumps-rubella vaccine against mumps and identified risk factors for disease transmission during a large outbreak in New York City, finding a two-dose vaccine effectiveness of 86.3% among secondary contacts.
DOI: 10.1016/j.vaccine.2013.11.021